{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Table 2"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Table 2","index":0,"n_rows":49,"n_cols":7,"rows_kept":49,"merged":[[1,2,1,3],[1,5,1,6],[48,0,48,6]],"flags":["formulas_cached_only"]}
[]
[null,null,"Univariate",null,null,"Multivariate"]
["Variable",null,"HR (95% CI)","p-Value",null,"HR (95% CI)","p-Value"]
["Age","≤70 years",1]
[null,">70 years","0.574 (0.247-1.335)",0.197]
[]
["Gender"]
[null,"Male",1]
[null,"Female","1.507 (0.636-3.568)",0.351]
[]
["ECOG PS"]
[null,0,1,null,null,1]
[null,1,"1.529 (0.614-3.812)",0.362,null,"0.786 (0.259-2.387)",0.672]
[null,2,"12.241 (2.806-53.394)","<0.001",null,"9.994 (1.854-53.879)",0.007]
[]
["Histology","Pure UC",1]
[null,"Mixed UC","0.332 (0.078-1.419)",0.137]
[]
["Hb"]
[null,"≥10 g/dl",1]
[null,"<10 g/dl","1.321 (0.492-3.260)",0.562]
[]
["NLR"]
[null,"< 2.0",1]
[null,"≥ 2.0","1.774 (0.758-4.149)",0.186]
[]
["Albumin"]
[null,"≥4.1 g/dl",1]
[null,"<4.1 g/dl","1.232 (0.531-2.857)",0.627]
[]
["LDH"]
[null,"≤222 U/L",1,null,null,1]
[null,">222 U/L","3.878 (1.623-9.266)",0.002,null,"3.394 (0.957-12.035)",0.058]
[]
["Liver metastases"]
[null,"Negative",1,null,null,1]
[null,"Positive","3.616 (1.348-8.914)",0.013,null,"3.751 (0.958-13.603)",0.047]
[]
["Time from previous chemotherapy"]
[null,"< 3 months",1,null,null,1]
[null,"≥ 3 months","0.219 (0.077-0.632)",0.006,null,"0.094 (0.023-0.357)","<0.001"]
[]
["Number of chemotheray cycles before pembrolizumab"]
[null,"≤4 cycles",1,null,null,1]
[null,">4 cycles","0.346 (0.124-0.962)",0.042,null,"0.745 (0.225-2.467)",{"v":0.63,"d":"0.630"}]
[]
[null,"≤6 cycles",1]
[null,">6 cycles","1.260 (0.452-3.510)",0.658]
["ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; Hb, hemoglobin; NLR, neutrophil/lymphocyte ratio; LDH, lactate dehydrogenase; HR, hazard ratio; CI, confidence interval"]